EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience

BACKGROUND: About 15% of non-small cell lung cancers (NSCLCs) harbor epidermal growth factor receptor (EGFR) mutations. Upfront treatment with first and second generation EGFR tyrosine kinase inhibitors (1-2gen TKIs) is superior to chemotherapy. The most frequent resistance mechanism to 1-2gen TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Maso, Alessandro, Del Bianco, Paola, Cortiula, Francesco, Nardo, Giorgia, Zulato, Elisabetta, Bonanno, Laura, Follador, Alessandro, De Maglio, Giovanna, Pasello, Giulia, Indraccolo, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562526/
https://www.ncbi.nlm.nih.gov/pubmed/36245580
http://dx.doi.org/10.21037/jtd-22-745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562526/
https://www.ncbi.nlm.nih.gov/pubmed/36245580
http://dx.doi.org/10.21037/jtd-22-745

Ejemplares similares